COVID-19

Intestinal attenuation of COVID-19 inflammation

Subjects

Gastrointestinal (GI) symptoms are observed in patients with COVID-19, but the link between GI immune responses and disease outcomes is unclear. This preprint shows that COVID-19 severity and mortality, and levels of circulating inflammatory cytokines, are reduced in patients with GI symptoms. The SARS-CoV-2 receptor ACE2 was highly expressed in small intestinal enterocytes and viral particles were detected in these cells in patients with COVID-19. GI inflammation was absent in patients with COVID-19, as shown by a reduction of cellular inflammatory subsets and downregulation of inflammatory pathways. This study provides a basis for exploring the mechanisms involved in attenuation of SARS-CoV-2-associated GI inflammation to aid a comprehensive understanding of organ-specific immune responses in COVID-19.

References

Original article

  1. Livanos, A. E. et al. Gastrointestinal involvement attenuates COVID-19 severity and mortality. Preprint at medRxiv https://doi.org/10.1101/2020.09.07.20187666 (2020)

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Aljawharah Alrubayyi.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Alrubayyi, A. Intestinal attenuation of COVID-19 inflammation. Nat Rev Immunol 20, 719 (2020). https://doi.org/10.1038/s41577-020-00466-y

Download citation

Search

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing